<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705169</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5377</org_study_id>
    <secondary_id>38508</secondary_id>
    <secondary_id>TDU15867</secondary_id>
    <nct_id>NCT03705169</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of SAR441236</brief_title>
  <official_title>A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the&#xD;
      human immunodeficiency virus (HIV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity&#xD;
      of SAR441236, a tri-specific broadly neutralizing antibody against HIV.&#xD;
&#xD;
      The study includes three arms. In Arm A, three cohorts of antiretroviral-treated,&#xD;
      virologically suppressed participants will be randomized to receive a single intravenous (IV)&#xD;
      dose of SAR441236 or placebo on Day 0. After Cohort 1, each subsequent cohort will open for&#xD;
      enrollment only after an evaluation of safety outcomes for all participants in the previous&#xD;
      cohort indicates that it is safe to increase the dose of SAR441236. All participants in&#xD;
      Cohorts 1-3 will be followed for 24 weeks.&#xD;
&#xD;
      In Arm A, Cohort 4, participants will be randomized to receive an IV infusion of SAR441236 or&#xD;
      placebo once every 12 weeks beginning at entry, for a total of 4 infusions. Participants in&#xD;
      this cohort will be followed for 36 weeks after their final infusion.&#xD;
&#xD;
      Participants in Arm A will continue taking non-study-provided antiretroviral treatment&#xD;
      throughout the study.&#xD;
&#xD;
      In Arm B, five cohorts of viremic participants will each receive a single IV dose of&#xD;
      SAR441236 on Day 0. Each subsequent Arm B cohort will be opened for enrollment only after an&#xD;
      evaluation of efficacy data from Day 14 for all participants in the previous cohort. All Arm&#xD;
      B participants will be followed for 24 weeks.&#xD;
&#xD;
      Participants in Arm B will initiate or re-initiate non-study-provided combination&#xD;
      antiretroviral therapy (ART) (selected by their primary HIV clinician) on Day 28.&#xD;
&#xD;
      In Arm C, two cohorts of ART-treated, virologically suppressed participants each will be&#xD;
      randomized to receive a single subcutaneous (SC) dose of SAR441236 or placebo on Day 0.&#xD;
      Cohort 11 will open for enrollment only after an evaluation of safety outcomes from Day 14&#xD;
      for all participants in Cohort 10 and the cumulative data from all the previous cohorts&#xD;
      indicates it is safe to dose escalate. All Arm C participants will be followed for 24 weeks.&#xD;
&#xD;
      Participants in Arm C will continue taking non-study-provided ART throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Anticipated">February 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of a Grade 3 or higher adverse event (AE) that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arms A and C) any time from study treatment administration through the entire follow-up</measure>
    <time_frame>Measured through 36 weeks after final infusion for Cohort 4</time_frame>
    <description>Based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of a Grade 3 or higher AE that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arms A and C) any time from study treatment administration through the entire follow-up</measure>
    <time_frame>Measured through Week 24 for Cohorts 1-3 and Arms B and C cohorts</time_frame>
    <description>Based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC12wk of SAR441236</measure>
    <time_frame>Measured through Week 12</time_frame>
    <description>As assessed by pharmacokinetic sampling and analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to the treatment initiation) to Day 7 of monotherapy for viremic participants with HIV (Arm B cohorts)</measure>
    <time_frame>Measured through Day 7</time_frame>
    <description>Based on laboratory evaluations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA (copies/mL) from baseline and post infusion for viremic participants with HIV (Arm B cohorts)</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to treatment initiation) to Day 14 and Day 28 of monotherapy for Arm B cohorts</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum reduction of plasma HIV-1 RNA during 28 days of monotherapy for viremic participants with HIV (Arm B cohorts)</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attributions of anti-SAR441236 antibodies</measure>
    <time_frame>Measured through Week 24 for Cohorts 1-3 and Arms B and C cohorts</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attributions of anti-SAR441236 antibodies</measure>
    <time_frame>Measured through 36 weeks after final infusion for Cohort 4</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following single dose of SAR441236 for all cohorts</measure>
    <time_frame>Measured through Week 12</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to half life of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution volume of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts</measure>
    <time_frame>Measured through Week 24</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to half life of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution volume of SAR441236 after each infusion for Cohort 4</measure>
    <time_frame>Measured through 36 weeks after final infusion</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish concentration (or dose)-response relationship between SAR441236 exposure and changes in plasma HIV-1 RNA from entry baseline to week 4 (or viral load nadir) for Arm B cohorts</measure>
    <time_frame>Measured through Week 4</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Arm A, Cohort 1A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 1B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 2A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 2B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 3A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 3B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 4A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Cohort 4B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Cohort 5: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Cohort 6: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Cohort 7: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Cohort 8: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Cohort 9: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C, Cohort 10A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C, Cohort 10B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C, Cohort 11A: SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C, Cohort 11B: Placebo for SAR441236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAR441236</intervention_name>
    <description>Administered by intravenous (IV) infusion or subcutaneous (SC) injection</description>
    <arm_group_label>Arm A, Cohort 1A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 2A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 3A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 4A: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 5: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 6: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 7: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 8: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 9: SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 10A: SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 11A: SAR441236</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by intravenous (IV) infusion or subcutaneous (SC) injection</description>
    <arm_group_label>Arm A, Cohort 1B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 2B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 3B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 4B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 10B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 11B: Placebo for SAR441236</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral treatment</intervention_name>
    <description>Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.</description>
    <arm_group_label>Arm A, Cohort 1A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 1B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 2A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 2B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 3A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 3B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 4A: SAR441236</arm_group_label>
    <arm_group_label>Arm A, Cohort 4B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 5: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 6: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 7: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 8: SAR441236</arm_group_label>
    <arm_group_label>Arm B, Cohort 9: SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 10A: SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 10B: Placebo for SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 11A: SAR441236</arm_group_label>
    <arm_group_label>Arm C, Cohort 11B: Placebo for SAR441236</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria, Arms A, B, and C&#xD;
&#xD;
          -  HIV-1 infection, documented by any licensed rapid HIV-1 test or HIV-1 enzyme or&#xD;
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and&#xD;
             confirmed by a licensed Western blot, Geenius assay, or a second antibody test by a&#xD;
             method other than the initial rapid HIV-1 and/or E/CIA, or by HIV-1 antigen, plasma&#xD;
             HIV-1 RNA viral load.&#xD;
&#xD;
               -  NOTE: The term &quot;licensed&quot; refers to a US Food and Drug Administration&#xD;
                  (FDA)-approved kit.&#xD;
&#xD;
               -  WHO (World Health Organization) and CDC (Centers for Disease Control and&#xD;
                  Prevention) guidelines mandate that confirmation of the initial test result must&#xD;
                  use a test that is different from the one used for the initial assessment. A&#xD;
                  reactive initial rapid test should be confirmed by either another type of rapid&#xD;
                  assay or an E/CIA that is based on a different antigen preparation and/or&#xD;
                  different test principle (e.g., indirect versus competitive), or a Western blot,&#xD;
                  Geenius assay, or a plasma HIV-1 RNA viral load.&#xD;
&#xD;
          -  The following laboratory values obtained within 45 days prior to entry by any US&#xD;
             laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification&#xD;
             or its equivalent.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 1500 cells/mm^3&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 12.0 g/dL for men and greater than or equal&#xD;
                  to 11.0 g/dL for women&#xD;
&#xD;
               -  Platelet count greater than or equal to 120,000/mm^3&#xD;
&#xD;
               -  Creatinine clearance (CrCl) greater than 60 mL/min&#xD;
&#xD;
                    -  Refer to the calculator located on the FSTRF website (at&#xD;
                       https://www.frontierscience.org/): Calculated Creatinine Clearance -&#xD;
                       Cockcroft-Gault Equation (Adult).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (SGOT) less than 1.25 x upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) (SGPT) less than 1.25 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase less than 2.0 x ULN&#xD;
&#xD;
               -  Total bilirubin less than 1.1 x ULN&#xD;
&#xD;
          -  Hepatitis C virus (HCV) antibody negative result within 45 days prior to study entry&#xD;
             or, for study candidates who are HCV antibody positive (based on testing performed at&#xD;
             any time prior to study entry), a negative HCV RNA result obtained within 45 days&#xD;
             prior to study entry.&#xD;
&#xD;
               -  NOTE: A negative HCV RNA level may result from either spontaneous clearance or&#xD;
                  from HCV therapy. Participants must have completed any HCV therapy at least 6&#xD;
                  months prior to enrollment.&#xD;
&#xD;
          -  Negative HBsAg result obtained within 45 days prior to study entry, or documented&#xD;
             hepatitis B immunity, defined as positive hepatitis B surface antibody testing, at any&#xD;
             time.&#xD;
&#xD;
          -  Female study candidates of reproductive potential must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 25 mIU/mL performed at screening and&#xD;
             again within 24 hours before study entry by any US clinic or laboratory that has a&#xD;
             CLIA certification or its equivalent, or is using a point of care (POC)/CLIA-waived&#xD;
             test.&#xD;
&#xD;
               -  NOTE: Reproductive potential is defined as girls who have reached menarche, and&#xD;
                  women who have not been post-menopausal for at least 24 consecutive months, i.e.,&#xD;
                  who have had menses within the preceding 24 months, and women who have not&#xD;
                  undergone surgical sterilization, specifically hysterectomy and/or bilateral&#xD;
                  oophorectomy.&#xD;
&#xD;
          -  All study candidates must agree not to participate in an assisted conception process&#xD;
             (e.g., sperm donation, intrauterine insemination, in vitro fertilization) from&#xD;
             screening until 12 weeks after the final study visit.&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, all study candidates&#xD;
             must agree to use at least one reliable method of contraception from study entry until&#xD;
             12 weeks after the final study visit. At least one of the following methods must be&#xD;
             used appropriately:&#xD;
&#xD;
               -  Condoms (male or female) with or without a spermicidal agent. Condoms are&#xD;
                  recommended because their appropriate use is the only contraception method&#xD;
                  effective for preventing HIV transmission.&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide.&#xD;
&#xD;
               -  Intrauterine device.&#xD;
&#xD;
               -  Hormone-based contraceptive.&#xD;
&#xD;
          -  Study candidates who are not of reproductive potential are eligible without requiring&#xD;
             the use of a contraceptive method. Acceptable documentation of sterilization,&#xD;
             menopause, and reproductive potential is specified below.&#xD;
&#xD;
               -  Written documentation or oral communication from a clinician or clinician's staff&#xD;
                  documented in source documents of one of the following:&#xD;
&#xD;
                    -  Physician report/letter&#xD;
&#xD;
                    -  Operative report or other source documentation in the patient record&#xD;
&#xD;
                    -  Discharge summary&#xD;
&#xD;
                    -  Laboratory report of azoospermia (is required to document successful&#xD;
                       vasectomy)&#xD;
&#xD;
                    -  Follicle-stimulating hormone (FSH) measurement elevated into the menopausal&#xD;
                       range as established by the reporting laboratory.&#xD;
&#xD;
               -  NOTE A: Female reproductive potential is defined in the criteria above.&#xD;
&#xD;
               -  NOTE B: Male candidates who are not of reproductive potential are defined as&#xD;
                  having documented azoospermia.&#xD;
&#xD;
               -  NOTE C: A female study candidate's oral report of her male partner's lack of&#xD;
                  reproductive potential should be recorded in the source documents if written&#xD;
                  proof is not available.&#xD;
&#xD;
          -  Individuals age greater than or equal to 18 years and less than or equal to 70 years&#xD;
             at study entry.&#xD;
&#xD;
          -  Ability and willingness of participant to provide informed consent.&#xD;
&#xD;
        Additional Arms A- and C-specific Inclusion Criteria&#xD;
&#xD;
          -  Receiving combination ART for at least 12 months prior to study entry with no changes&#xD;
             in ART regimen within the 12 weeks prior to entry.&#xD;
&#xD;
               -  NOTE A: Use of a two-drug ART regimen within the 12 months prior to entry is&#xD;
                  exclusionary.&#xD;
&#xD;
               -  NOTE B: Although ritonavir or cobicistat may be included in a combination ART&#xD;
                  regimen, neither of these &quot;counts&quot; in a tally of antiretroviral agents.&#xD;
&#xD;
          -  CD4+ cell count of greater than or equal to 200 cells/mm^3 obtained within 45 days&#xD;
             prior to study entry at any US laboratory that has a CLIA certification or its&#xD;
             equivalent.&#xD;
&#xD;
          -  Within 45 days prior to study entry, plasma HIV-1 RNA &lt;50 copies/mL on any&#xD;
             FDA-approved assay with a limit of quantification of &lt;50 copies/mL by a US laboratory&#xD;
             that has a CLIA certification or its equivalent.&#xD;
&#xD;
          -  Within 12 months prior to study entry and before screening, at least one documented&#xD;
             plasma HIV-1 RNA &lt;50 copies/mL on any FDA-approved assay with a limit of&#xD;
             quantification of &lt;50 copies/mL by a US laboratory that has a CLIA certification or&#xD;
             its equivalent.&#xD;
&#xD;
               -  NOTE: A single plasma HIV-1 RNA ≥50 but &lt;200 copies/mL at least 6 months prior to&#xD;
                  screening is permitted if followed within 2 months by an HIV-1 RNA &lt;50 copies/mL.&#xD;
&#xD;
        Additional Arm B-specific Inclusion Criteria&#xD;
&#xD;
          -  Plasma HIV-1 RNA &gt;5000 and ≤200,000 copies/mL within 45 days prior to study entry.&#xD;
&#xD;
          -  CD4+ cell count of greater than or equal to 350 cells/mm^3 obtained within 45 days&#xD;
             prior to study entry at any US laboratory that has a CLIA certification or its&#xD;
             equivalent.&#xD;
&#xD;
          -  Willingness and ability to start or re-start combination ART by or on Day 28 of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria, Arms A, B, and C&#xD;
&#xD;
          -  Breastfeeding or plans to become pregnant.&#xD;
&#xD;
          -  Receipt of chimeric, humanized or human long-acting mAbs, whether licensed or&#xD;
             investigational, within 12 months prior to entry, or receipt of chimeric, humanized or&#xD;
             human regular mAbs, whether licensed or investigational, within 6 months prior to&#xD;
             entry, unless reviewed and approved by the study's core team.&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to components of study treatment or&#xD;
             its formulation (refer to the product's Investigator's Brochure).&#xD;
&#xD;
          -  Vaccination within 30 days prior to entry or intent to receive an elective vaccination&#xD;
             (e.g., hepatitis A vaccine, travel-related) during the course of the study except as&#xD;
             noted in the study protocol.&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Acute or serious illness requiring systemic treatment and/or hospitalization within 45&#xD;
             days prior to entry.&#xD;
&#xD;
          -  Diagnosis of AIDS-defining illness using the current list on the US Centers for&#xD;
             Disease Control and Prevention (CDC) website within 1 year prior to entry.&#xD;
&#xD;
          -  Weight greater than 115 kg within 45 days prior to study entry.&#xD;
&#xD;
          -  Use of maraviroc, ibalizumab, or enfuvirtide at any time.&#xD;
&#xD;
        Additional Arms A- and C-specific Exclusion Criterion&#xD;
&#xD;
          -  Within 6 months prior to study entry, any plasma HIV-1 RNA ≥50 copies/mL on any&#xD;
             FDA-approved assay with a limit of quantification of &lt;50 copies/mL performed by a US&#xD;
             laboratory that has a CLIA certification or its equivalent.&#xD;
&#xD;
        Additional Arm B-specific Exclusion Criterion&#xD;
&#xD;
          -  Use of any anti-HIV ART, including FDA-approved pre-exposure prophylaxis (PrEP) within&#xD;
             the preceding 3 months&#xD;
&#xD;
        Additional Arm C-specific Exclusion Criterion&#xD;
&#xD;
          -  Presence of abdominal scarring or tattooing that could interfere with assessment of&#xD;
             injection-site reaction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athe Tsibris, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel R. Kuritzkes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital Therapeutics CRS, Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Tebas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Penn Therapeutics CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Heard, M.P.H.</last_name>
      <phone>205-996-4405</phone>
      <email>fhoward@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleen Khodabakhshian</last_name>
      <phone>310-557-9027</phone>
      <email>akhodabakhshian@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Dwyer</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>353</phone_ext>
      <email>Jay.Dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@labiomed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo, M.S.P.H.</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick, M.S.N.</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins, M.P.H.</last_name>
      <phone>312-695-5012</phone>
      <email>Baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mall, R.N.</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N.</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl E. Keenan, R.N.</last_name>
      <phone>617-732-5635</phone>
      <email>CKeenan@BWH.Harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K. Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rondalya DeShields, R.N., B.S.N.</last_name>
      <phone>973-972-3729</phone>
      <email>deshierd@njms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Stroberg, R.N., B.S.N.</last_name>
      <phone>212-746-7198</phone>
      <email>tstrober@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Palmer, P.A. -C</last_name>
      <phone>212-342-2958</phone>
      <email>sp500@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, M.S.N., FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Adult HIV Therapeutic Strategies Network CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hurley</last_name>
      <phone>585-210-4136</phone>
      <email>Christine_Hurley@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs, R.N., B.S.N.</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Baum, R.N.</last_name>
      <phone>216-844-2546</phone>
      <email>jb@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson, B.S.N., R.N.</last_name>
      <phone>614-293-5856</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics, CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Baer</last_name>
      <phone>215-349-5023</phone>
      <email>Baer2@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn R. Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital Clinical Research Site (TMH CRS) CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Poethke, R.N.</last_name>
      <phone>401-793-4971</phone>
      <email>ppoethke@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly O. Woodward, M.S.N., R.N.</last_name>
      <phone>615-936-8516</phone>
      <email>beverly.o.woodward@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jonsson, EMBA</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia I. Davila Nieves, M.Sc.</last_name>
      <phone>787-767-9192</phone>
      <email>sylvia.davila1@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>broadly neutralizing antibody</keyword>
  <keyword>antiretroviral</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?&#xD;
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses?&#xD;
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available?&#xD;
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

